Show simple item record

dc.contributor.authorYang, Xiao-Ying
dc.contributor.authorWang, Li-Qiong
dc.contributor.authorLi, Jin-Gen
dc.contributor.authorLiang, Ning
dc.contributor.authorWang, Ying
dc.contributor.authorLiu, Jian-Ping
dc.date.accessioned2019-05-14T14:32:16Z
dc.date.available2019-05-14T14:32:16Z
dc.date.issued2017-12-09
dc.description.abstract<i>Objective</i>: The existing eligible randomized controlled trials (RCTs) were critically appraised for the effectiveness and safety of Chinese herbal medicine Dengzhan Shenmai for ischemic stroke.<p> <p><i>Design</i>: Systematic review and meta-analysis (CRD42016042914, http://www.crd.york.ac.uk/PROSPERO). Methods: Six electronic databases were searched from inception to May 2016. Risk ratio (RR) and mean difference (MD) with a 95% confidence interval (CI) were used as effect estimates using RevMan 5.3. Meta-analysis was performed where data were available. A summary of finding table was generated by the GRADEpro (version 3.6).<p> <p><i>Results</i>: We identified 14 RCTs involving 5206 participants. Majority of the included trials were of high risk of bias in methodological quality. For acute ischemic stroke, adding DZSM capsule to conventional therapy achieved higher Barthel Index scores (MD 22.37, 95% CI 21.34–23.40), lower neurological function deficit scores (MD – 3.73, 95% CI −5.27 to −2.19) and lower recurrence rate (RR 0.22, 95% CI 0.10, 0.46). For patients in their convalescence (or sequelae) stage of ischemic stroke, DZSM capsule was superior in improving quality of life (MD 28.8, 95% CI 7.10–50.50) and recurrence rate (RR 0.71, 95% CI 0.51–0.99) compared to placebo. No trials reported serious adverse events.<p> <p><i>Conclusion</i>: DZSM capsule appears to improve neurological function, quality of life, and reduce recurrence rate based on conventional therapy for ischemic stroke. DZSM capsule seems generally safe for clinical application. However, the findings of benefit are inconclusive due to generally weak evidence, and further large, rigorous trials are still warranted.<p>en_US
dc.description.sponsorshipState Administration of Chinese Medicine Yunnan Biovalley Pharmaceuticalsen_US
dc.descriptionSource at <a href=https://doi.org/10.1016/j.ctim.2017.12.004>https://doi.org/10.1016/j.ctim.2017.12.004. </a>en_US
dc.identifier.citationYang, X-Y.,, Wang, L-Q., Li, J-G., Liang, N., Wang, Y. & Liu, J-P. (2018). Chinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: A systematic review and meta-analysis of randomized clinical trials. <i>Complementary Therapies in Medicine, 36</i>, 82-89. https://doi.org/10.1016/j.ctim.2017.12.004en_US
dc.identifier.cristinIDFRIDAID 1623716
dc.identifier.doi10.1016/j.ctim.2017.12.004
dc.identifier.issn0965-2299
dc.identifier.issn1873-6963
dc.identifier.urihttps://hdl.handle.net/10037/15309
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalComplementary Therapies in Medicine
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en_US
dc.subjectChinese patent medicineen_US
dc.subjectDengzhan shengmaien_US
dc.subjectIschemic strokeen_US
dc.subjectRandomized controlled trialsen_US
dc.subjectSystematic reviewen_US
dc.subjectMeta-analysisen_US
dc.titleChinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: A systematic review and meta-analysis of randomized clinical trialsen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record